Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Ane Ogbe Clear advanced filters

  • Understanding the immune response to SARS-CoV-2 is dependent on being able to distinguish COVID-19 immune responses from cross-reactive immune responses to other coronaviruses. Here the authors show that choice of antigens and whether an ICS, ELISPOT or T cell proliferation assay is used has a major effect on this discriminatory ability.

    • Ane Ogbe
    • Barbara Kronsteiner
    • Susanna Dunachie
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-14

  • The engagement of immunological memory is a key component to the protective anti-SARS-CoV-2 B and T cell responses. Here the authors assess the B and T cells of a cohort of UK healthcare workers in response to infection and longitudinally track the compartment showing distinct trajectories following early priming.

    • Adriana Tomic
    • Donal T. Skelly
    • Susanna J. Dunachie
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-20

  • Remdesivir is under evaluation for treatment of COVID-19 in clinical trials. Here, the authors report results of remdesivir treatment in a patient with COVID-19 and the genetic antibody deficiency XLA. They show a temporally correlated clinical and virological response, suggesting that remdesivir can reduce SARS-CoV-2 replication in patients.

    • Matthew S. Buckland
    • James B. Galloway
    • James E. D. Thaventhiran
    ResearchOpen Access
    Nature Communications
    Volume: 11, P: 1-11

  • Elucidation of broadly neutralizing antibodies (bnAb) is a goal in HIV vaccine development. Here, Bradley et al. show that administration of CTLA-4 blocking antibody with vaccine antigens increases HIV-1 envelope antibody responses in macaques and a bnAb precursor mouse model.

    • Todd Bradley
    • Masayuki Kuraoka
    • Barton F. Haynes
    ResearchOpen Access
    Nature Communications
    Volume: 11, P: 1-16

  • This Review discusses the evidence for pre-existing cross-reactive immune responses to SARS-CoV-2, which are mainly due to infections with common cold coronaviruses, and how such cross-reactivity affects adaptive immune responses. Furthermore, it explores cross-reactivity in the context of SARS-CoV-2 variants of concern and its implications for vaccine development.

    • Sam M. Murray
    • Azim M. Ansari
    • Ane Ogbe
    Reviews
    Nature Reviews Immunology
    Volume: 23, P: 304-316

  • Understanding the effect of vaccination on emerging SARS-CoV-2 variants of concern is of increasing importance. Here, James et al. report that two doses of vaccination with the Pfizer-BioNTech vaccine induce more robust immune responses to the B.1.1.7 and B.1.351 SARS-CoV-2 lineages than does natural infection.

    • Donal T. Skelly
    • Adam C. Harding
    • William S. James
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-12